Bayer files Eylea for DME approval in the EU
This article was originally published in Scrip
Executive Summary
Bayer Healthcare has filed Eylea (aflibercept solution for injection (VEGF Trap-EYE)) for use in the additional indication of diabetic macular edema (DME) in the EU.